ES2966638T3 - Ambrisentan para su uso en el tratamiento de insuficiencia renal aguda - Google Patents
Ambrisentan para su uso en el tratamiento de insuficiencia renal aguda Download PDFInfo
- Publication number
- ES2966638T3 ES2966638T3 ES20175547T ES20175547T ES2966638T3 ES 2966638 T3 ES2966638 T3 ES 2966638T3 ES 20175547 T ES20175547 T ES 20175547T ES 20175547 T ES20175547 T ES 20175547T ES 2966638 T3 ES2966638 T3 ES 2966638T3
- Authority
- ES
- Spain
- Prior art keywords
- ambrisentan
- administered
- subject
- kidney
- liquid composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/70—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving creatine or creatinine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310221P | 2016-03-18 | 2016-03-18 | |
| EP16166046.9A EP3235496A1 (en) | 2016-04-19 | 2016-04-19 | Treatment of acute renal failure |
| US201662437949P | 2016-12-22 | 2016-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2966638T3 true ES2966638T3 (es) | 2024-04-23 |
Family
ID=55808404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES20175547T Active ES2966638T3 (es) | 2016-03-18 | 2017-03-20 | Ambrisentan para su uso en el tratamiento de insuficiencia renal aguda |
| ES17711211T Active ES2856960T3 (es) | 2016-03-18 | 2017-03-20 | Ambrisentan para uso en el tratamiento de insuficiencia renal aguda |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17711211T Active ES2856960T3 (es) | 2016-03-18 | 2017-03-20 | Ambrisentan para uso en el tratamiento de insuficiencia renal aguda |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10870021B2 (enExample) |
| EP (3) | EP3235496A1 (enExample) |
| JP (1) | JP7237362B2 (enExample) |
| KR (1) | KR20180121539A (enExample) |
| CN (1) | CN109069443A (enExample) |
| AU (1) | AU2017235618B2 (enExample) |
| BR (1) | BR112018067602A2 (enExample) |
| CA (1) | CA3015432A1 (enExample) |
| CL (1) | CL2018002638A1 (enExample) |
| DK (1) | DK3429566T3 (enExample) |
| ES (2) | ES2966638T3 (enExample) |
| HK (1) | HK1259616A1 (enExample) |
| IL (1) | IL261457B (enExample) |
| MX (1) | MX374534B (enExample) |
| SG (1) | SG11201808009SA (enExample) |
| WO (1) | WO2017158199A1 (enExample) |
| ZA (1) | ZA201805562B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3639827A1 (en) | 2018-10-19 | 2020-04-22 | Noorik Biopharmaceuticals AG | Use of ambrisentan for the treatment of portal hypertension and cirrhosis |
| EP4142731A1 (en) * | 2020-04-28 | 2023-03-08 | Noorik Biopharmaceuticals AG | Treatment of pulmonary complications of coronavirus infections |
| WO2021219691A1 (en) * | 2020-04-29 | 2021-11-04 | Astrazeneca Ab | Dapagliflozin and ambrisentan for the prevention and treatment of covid-19 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19533023B4 (de) | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| CN101801936B (zh) * | 2007-07-31 | 2012-10-03 | 吉利德科罗拉多公司 | 安立生坦的代谢物和衍生物 |
| US9255931B2 (en) | 2010-06-24 | 2016-02-09 | Morehouse School Of Medicine | Method and compositions for the treatment and detection of endothelin-1 related kidney diseases |
| US20150030564A1 (en) | 2012-02-29 | 2015-01-29 | Toray Industries, Inc. | Inhibitory agent for body cavity fluid accumulation |
| JP2016512201A (ja) * | 2013-03-08 | 2016-04-25 | アッヴィ・インコーポレイテッド | 急性腎障害の治療方法 |
| CN105592855A (zh) | 2013-04-26 | 2016-05-18 | 拉卓拉药物公司 | 用于治疗肾衰竭的组合物和方法 |
| US20150125546A1 (en) * | 2013-11-06 | 2015-05-07 | Gilead Sciences, Inc. | Combination therapy for treating pulmonary hypertension |
-
2016
- 2016-04-19 EP EP16166046.9A patent/EP3235496A1/en not_active Withdrawn
-
2017
- 2017-03-20 EP EP17711211.7A patent/EP3429566B1/en active Active
- 2017-03-20 HK HK19101803.4A patent/HK1259616A1/zh unknown
- 2017-03-20 MX MX2018011222A patent/MX374534B/es active IP Right Grant
- 2017-03-20 ES ES20175547T patent/ES2966638T3/es active Active
- 2017-03-20 EP EP20175547.7A patent/EP3878439B1/en active Active
- 2017-03-20 JP JP2019500021A patent/JP7237362B2/ja active Active
- 2017-03-20 DK DK17711211.7T patent/DK3429566T3/da active
- 2017-03-20 AU AU2017235618A patent/AU2017235618B2/en active Active
- 2017-03-20 WO PCT/EP2017/056476 patent/WO2017158199A1/en not_active Ceased
- 2017-03-20 US US16/084,340 patent/US10870021B2/en active Active
- 2017-03-20 KR KR1020187026495A patent/KR20180121539A/ko not_active Ceased
- 2017-03-20 SG SG11201808009SA patent/SG11201808009SA/en unknown
- 2017-03-20 CN CN201780017563.3A patent/CN109069443A/zh active Pending
- 2017-03-20 CA CA3015432A patent/CA3015432A1/en active Pending
- 2017-03-20 BR BR112018067602A patent/BR112018067602A2/pt not_active Application Discontinuation
- 2017-03-20 ES ES17711211T patent/ES2856960T3/es active Active
-
2018
- 2018-08-21 ZA ZA2018/05562A patent/ZA201805562B/en unknown
- 2018-08-29 IL IL261457A patent/IL261457B/en unknown
- 2018-09-14 CL CL2018002638A patent/CL2018002638A1/es unknown
-
2020
- 2020-10-07 US US17/065,097 patent/US11642307B2/en active Active
-
2023
- 2023-03-31 US US18/129,516 patent/US20230233454A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2856960T3 (es) | 2021-09-28 |
| IL261457A (en) | 2018-10-31 |
| CA3015432A1 (en) | 2017-09-21 |
| EP3429566B1 (en) | 2021-01-27 |
| MX2018011222A (es) | 2019-01-10 |
| IL261457B (en) | 2021-09-30 |
| US11642307B2 (en) | 2023-05-09 |
| EP3429566A1 (en) | 2019-01-23 |
| MX374534B (es) | 2025-03-06 |
| ZA201805562B (en) | 2019-06-26 |
| SG11201808009SA (en) | 2018-10-30 |
| JP2019515942A (ja) | 2019-06-13 |
| AU2017235618B2 (en) | 2021-02-25 |
| US20230233454A1 (en) | 2023-07-27 |
| US20190083820A1 (en) | 2019-03-21 |
| US20210046332A1 (en) | 2021-02-18 |
| CL2018002638A1 (es) | 2019-01-18 |
| DK3429566T3 (da) | 2021-03-29 |
| EP3878439A1 (en) | 2021-09-15 |
| EP3878439B1 (en) | 2023-10-04 |
| NZ746140A (en) | 2022-03-25 |
| WO2017158199A1 (en) | 2017-09-21 |
| AU2017235618A1 (en) | 2018-09-27 |
| CN109069443A (zh) | 2018-12-21 |
| BR112018067602A2 (pt) | 2019-01-08 |
| US10870021B2 (en) | 2020-12-22 |
| KR20180121539A (ko) | 2018-11-07 |
| EP3235496A1 (en) | 2017-10-25 |
| HK1259616A1 (zh) | 2019-12-06 |
| JP7237362B2 (ja) | 2023-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230233454A1 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| RU2640023C2 (ru) | Жидкий состав | |
| JP2019142964A (ja) | 眼内投与のためのエピネフリン系点眼用組成物及びその製造のための方法 | |
| AU2014346682B2 (en) | Novel formulations | |
| ES2906262T3 (es) | Composiciones para el tratamiento de la autodigestión | |
| AU2020204742C1 (en) | Vitamin E and cancer therapeutic compositions and methods | |
| US20200254059A1 (en) | Therapeutic agent of uremia containing alarin as the main ingredient | |
| Cousins et al. | Anaesthesia, surgery and renal function: immediate and delayed effects | |
| US20140107130A1 (en) | Oral Solution Formulations of Aripiprazole | |
| NZ746140B2 (en) | Ambrisentan for use in the treatment of acute renal failure | |
| US11883400B2 (en) | Treatment of portal hypertension and cirrhosis | |
| JP2023540771A (ja) | 炎症性腸疾患を治療する方法 | |
| NZ786075A (en) | Ambrisentan for use in the treatment of acute renal failure | |
| US20160256457A1 (en) | Methods for treating or preventing acute vascular leak | |
| US20260027094A1 (en) | Use of pyridone derivative | |
| US20190117624A1 (en) | Therapeutic agent for inflammatory bowel diseases | |
| Kumar et al. | Therapeutic Suppression of mTOR Signaling Prevents and Reverses Salt-Induced Hypertension and Kidney Injury in Dahl Salt-Sensitive Rats | |
| EP3955907A1 (en) | Pharmaceutical formulations containing p2y14 antagonists | |
| Skelly | Causes, consequences and control of potassium imbalances in small animals | |
| BR122024009541A2 (pt) | Composição compreendendo nintedanib para tratar doenças oculares com neovascularização anormal |